CN1297269C - 埃坡霉素衍生物用于治疗甲状旁腺功能亢进的用途 - Google Patents

埃坡霉素衍生物用于治疗甲状旁腺功能亢进的用途 Download PDF

Info

Publication number
CN1297269C
CN1297269C CNB200380101281XA CN200380101281A CN1297269C CN 1297269 C CN1297269 C CN 1297269C CN B200380101281X A CNB200380101281X A CN B200380101281XA CN 200380101281 A CN200380101281 A CN 200380101281A CN 1297269 C CN1297269 C CN 1297269C
Authority
CN
China
Prior art keywords
parathyroid
hyperparathyroidism
purposes
formula
epothilone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380101281XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1703217A (zh
Inventor
E·A·沃尔特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of CN1703217A publication Critical patent/CN1703217A/zh
Application granted granted Critical
Publication of CN1297269C publication Critical patent/CN1297269C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB200380101281XA 2002-10-15 2003-10-13 埃坡霉素衍生物用于治疗甲状旁腺功能亢进的用途 Expired - Fee Related CN1297269C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
US60/418,592 2002-10-15

Publications (2)

Publication Number Publication Date
CN1703217A CN1703217A (zh) 2005-11-30
CN1297269C true CN1297269C (zh) 2007-01-31

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200380101281XA Expired - Fee Related CN1297269C (zh) 2002-10-15 2003-10-13 埃坡霉素衍生物用于治疗甲状旁腺功能亢进的用途

Country Status (15)

Country Link
US (2) US20060142354A1 (enExample)
EP (1) EP1553938B1 (enExample)
JP (1) JP4672368B2 (enExample)
CN (1) CN1297269C (enExample)
AT (1) ATE350034T1 (enExample)
AU (1) AU2003267751A1 (enExample)
BR (1) BR0315293A (enExample)
CA (1) CA2501717C (enExample)
CY (1) CY1106385T1 (enExample)
DE (1) DE60310975T2 (enExample)
DK (1) DK1553938T3 (enExample)
ES (1) ES2279139T3 (enExample)
PT (1) PT1553938E (enExample)
SI (1) SI1553938T1 (enExample)
WO (1) WO2004035050A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292683A (zh) * 1998-02-05 2001-04-25 诺瓦提斯公司 含有有机化合物的组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1155689E (pt) * 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292683A (zh) * 1998-02-05 2001-04-25 诺瓦提斯公司 含有有机化合物的组合物

Also Published As

Publication number Publication date
HK1080768A1 (en) 2006-05-04
JP2006504751A (ja) 2006-02-09
DE60310975D1 (de) 2007-02-15
DE60310975T2 (de) 2007-07-12
CN1703217A (zh) 2005-11-30
ES2279139T3 (es) 2007-08-16
CY1106385T1 (el) 2011-10-12
AU2003267751A1 (en) 2004-05-04
US20110152329A1 (en) 2011-06-23
EP1553938A1 (en) 2005-07-20
CA2501717A1 (en) 2004-04-29
ATE350034T1 (de) 2007-01-15
CA2501717C (en) 2012-09-18
BR0315293A (pt) 2005-08-30
PT1553938E (pt) 2007-03-30
DK1553938T3 (da) 2007-03-26
US20060142354A1 (en) 2006-06-29
SI1553938T1 (sl) 2007-06-30
WO2004035050A1 (en) 2004-04-29
JP4672368B2 (ja) 2011-04-20
EP1553938B1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
US20090246172A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
JP2009173684A (ja) 腎臓結石疾患の予防のための希土類化合物の使用
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
US11026906B2 (en) Pharmaceutical quality strontium L-lactate
TW200808313A (en) Compositions and methods for treating rheumatoid arthritis
Bacci et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy
CN1297269C (zh) 埃坡霉素衍生物用于治疗甲状旁腺功能亢进的用途
MXPA04010853A (es) Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer.
US4517309A (en) Method for the treatment of calcifying pancreatitis
Taukumova et al. Mucocutaneous side effects and continuation of aurotherapy in patients with rheumatoid arthritis
HK1080768B (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
AU2002366531B2 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
US12208092B2 (en) Compositions and methods for administering paltusotine to patients with hepatic impairment
JPWO2004096230A1 (ja) 関節リウマチ治療剤
US20250295662A1 (en) Use of cdk4/6 inhibitor in treatment of dedifferentiated liposarcoma
AU2007200677B2 (en) Combinations comprising epothilones and anti-metabolites
JP2025521628A (ja) カルシニューリン阻害剤の間欠的投与のための組成物
HK1069983B (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome
CN101677978A (zh) 矫正骨吸收和骨形成失调的方法及其试剂盒和组合物
ZA200404013B (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome.
WO1993023066A1 (fr) Promoteur de croissance de plaquettes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070131

Termination date: 20131013